# Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

> **NCT03525392** · PHASE1 · TERMINATED · sponsor: **Ipsen** · enrollment: 14 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- Gastric Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Bone Cancer
- Advanced Cancer
- Recurrent Disease
- Metastatic Tumours

## Interventions

- **DRUG:** 177Lu-3BP-227 (also called 177Lu-IPN01087)

## Key facts

- **NCT ID:** NCT03525392
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-03
- **Primary completion:** 2020-04-03
- **Final completion:** 2021-04-28
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525392, "Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03525392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*